Multisystem inflammatory syndrome in children (MIS-C), believed to be linked to COVID-19, damages the heart to such an extent that some children will need lifelong monitoring and interventions, said the senior author of a medical literature review published Sept. 4 in EClinicalMedicine, a journal of The Lancet.
- Case studies also show MIS-C can strike seemingly healthy children without warning three or four weeks after asymptomatic infections, said Alvaro Moreira, MD, MSc, of The University of Texas Health Science Center at San Antonio. Dr. Moreira, a neonatologist, is an assistant professor of pediatrics in the university's Joe R. and Teresa Lozano Long School of Medicine.
- "According to the literature, children did not need to exhibit the classic upper respiratory symptoms of COVID-19 to develop MIS-C, which is frightening," Dr. Moreira said. "Children might have no symptoms, no one knew they had the disease, and a few weeks later, they may develop this exaggerated inflammation in the body."
Results
- The team reviewed 662 MIS-C cases reported worldwide between Jan. 1 and July 25. Among the findings:
- 71% of the children were admitted to the intensive care unit (ICU).
- 60% presented with shock.
- The average length of stay in the hospital was 7.9 days.
- 100% had a fever, 73.7% had abdominal pain or diarrhea, and 68.3% suffered vomiting.
- 90% had an echocardiogram (EKG) test and 54% of the results were abnormal.
- 22.2% of the children required mechanical ventilation.
- 4.4% required extracorporeal membrane oxygenation (ECMO).
- 11 children died.
- "This is a new childhood disease that is believed to be associated with SARS-CoV-2," Dr. Moreira said. "It can be lethal because it affects multiple organ systems. Whether it be the heart and the lungs, the gastrointestinal system, or the neurologic system, it has so many different faces that initially it was challenging for clinicians to understand."
The amount of inflammation in MIS-C surpasses two similar pediatric conditions, Kawasaki disease, and toxic shock syndrome. "The saving grace is that treating these patients with therapies commonly used for Kawasaki -immunoglobulin, and glucocorticosteroids - has been effective," Dr. Moreira said.
